98%
921
2 minutes
20
Purpose: The increasing incidence of colorectal cancer has coincided with a rise in T4 stage colon cancer (CC), yet research on its prognosis remains limited. This study aimed to identify risk factors and develop a nomogram to predict cancer-specific survival (CSS), optimizing treatment strategies for different subgroups.
Methods: Using data from the from the Surveillance, Epidemiology, and End Results (SEER) database, we identified risk factors in T4 stage CC patients and created a nomogram to predict CSS. Patients were divided into low- and high-risk groups, and the nomogram was validated. Propensity score matching was used to evaluate the benefits of various therapies across subgroups.
Results: Independent risk factors, including T stage, N stage, tumor grade, age, and therapy sequence, were identified through Cox regression analyses and incorporated into the nomogram. The nomogram outperformed the American Joint Committee on Cancer (AJCC) 7th staging system, with a Concordance-index of 0.77 in both training and validation sets. The receiver operating characteristic curves showed area under the curve values of 0.81, 0.77, and 0.75 for 1-, 3-, and 5-year CSS, respectively. Calibration plots confirmed strong alignment between predicted and actual outcomes, and decision curve analysis highlighted the nomogram's superior clinical utility. Chemotherapy significantly improved CSS, while radiation did not. Adjuvant therapy was particularly beneficial in high-risk groups.
Conclusion: This study offered a thorough prognostic analysis of T4 stage colon cancer patients and developed nomograms for predicting CSS. Subgroup analyses highlight the potential benefits of various treatment options.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920356 | PMC |
http://dx.doi.org/10.1007/s00384-025-04856-3 | DOI Listing |
Rep Pract Oncol Radiother
August 2025
Cardiac Surgery and Transplantology Department, Poznan University of Medical Sciences, Poznan, Poland.
Background: The rising burden of colorectal cancer with a high prevalence of advanced stages of new-onset is reported worldwide. While applied, chemotherapy can extend patients' survival, and proper tailoring is paramount. Based on computed tomography results, the study aimed to point out potential prognostic factors of complete or partial response to the initial three months of chemotherapy in palliative colorectal (CRC) cancer.
View Article and Find Full Text PDFKorean J Clin Oncol
August 2025
Division of Colon and Rectal Surgery, Department of Surgery, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
Purpose: This study aimed to analyze the benefit of neoadjuvant chemoradiation therapy (nCRT) versus adjuvant chemotherapy alone after surgery without nCRT on oncologic and perioperative outcomes of patients with extremely low rectal cancer requiring abdominoperineal resection (APR) when initially diagnosed.
Methods: Between March 2001 and December 2018, 88 patients who underwent APR for low rectal adenocarcinoma (anal verge < 4 cm) with clinical stage II and III (clinical T3/4, N -/+) were retrieved from a retrospective database. Sixty-eight patients received adjuvant chemotherapy alone after APR without nCRT, and 20 patients received nCRT before APR.
J Gastrointest Cancer
September 2025
Firoozabadi Clinical Research Development Unit (F A CRD U), Iran , University of Medical Sciences (IUMS), Tehran, Iran.
Background: Colorectal cancer (CRC) has become one of the major health burdens in the world with high mortality rates, especially at the advanced stages. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel multidimensional biomarker combining systemic inflammation, nutritional status, and immune function. This study evaluated the association between the CALLY index and overall survival (OS) as well as recurrence-free survival (RFS) in colorectal cancer (CRC) patients.
View Article and Find Full Text PDFJ Clin Gastroenterol
October 2025
Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine.
Goals: We aimed to characterize risk factors for early versus advanced-stage early-onset colorectal cancer (eoCRC) at our safety-net hospital system.
Background: Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in the United States. Rates of CRC diagnosis in young adults (age below 50) have been rising despite an overall decrease in CRC.
Front Oncol
August 2025
Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
Introduction: Proteases play an important role in tumor progression. The predictive efficacy of proteases PRSS3 and PRSS22 mRNA levels for predicting relapse in surgically treated colon cancer (CC) patients was assessed.
Methods: mRNA expression was quantified in 371 half lymph nodes (LNs) from 121 CC patients, 77 control LNs (13 patients), 66 primary colon tumors, and 30 normal colon tissues of these patients.